In Vitro Investigation of Recombinant Adenovirus-p53 Reversing the Resistance of Non-Small Cell Lung Cancer to Cisplatin

Lv Wangxia,Su Dan,Feng Jianguo,Mou Hanzhou,Gu Linhui,Ma Shenglin

DOI: https://doi.org/10.3969/j.issn.1673-5412.2008.05.002

2008-01-01

Abstract:Objective To provide experimental evidence of recombinant adenovirus-p53(rAd-p53) as a gene therapy applied to non-small cell lung cancer(NSCLC) patients who were resistant to cisplatin.Methods Inhibitory concentration 50%(IC50) was assayed by cell counting kit-8(CCK-8) reagent.The changes of cell cycle and apoptosis rate were analyzed by flow cytometer.The Gene Array was used to elucidate the change of the genes.Results Combining with the rAd-p53,the IC50 of H1299 cells to cisplatin was 5 μg/mL(P<0.05),and the apoptosis rate rose to 10.73%(P<0.05).Using the rAd-p53 only,the wild-type p53 gene was transferred into the H1299 cell line successfully.While using the cisplatin and rAd-p53 both,the p53 gene which had been transferred in the cell line activated the apoptosis mainly depending on Fas/Apo-1/CD95 system,TNFR supper family and Bcl-2/Bax,and at the same time,it also increased some cell-cycle regulating genes.Conclusion The rAd-p53 can become a promising adjuvant gene therapy of NSCLC patients who are resistant to cisplatin.